Entero Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
GridAI Technologies Corp. reports a major strategic pivot to AI-driven energy orchestration following the acquisition of Grid AI Corp. and the rescission of its ImmunogenX subsidiary.
10-K/A: Entero Therapeutics Faces Going Concern Doubts Amid Strategic Shifts and Financial Challenges
Entero Therapeutics reports ongoing losses and explores strategic alternatives, including a potential rescission agreement with ImmunogenX, raising concerns about its ability to continue as a going concern.
Entero Therapeutics' 10-K filing reveals significant operating losses and strategic realignments, raising substantial doubt about its ability to continue as a going concern.
First Wave BioPharma's 10-K filing outlines its capital stock structure, including common and preferred shares, and details recent transactions such as the ImmunogenX merger and a registered direct offering.